Colgate-Palmolive (India) Set to Benefit From Some Tailwinds -- Market Talk

Dow Jones05-25

0310 GMT - Colgate-Palmolive (India) stands to benefit from some tailwinds, Nomura analysts say in a research report. The Indian company's core product portfolio is recovering to normal levels from below-normal levels in FY 2026 and it's doubling down on product premiumization, the analysts note. The oral care products manufacturer's revenue growth momentum is likely to improve and return to near double digits in FY 2027 from flat in FY 2026. Nomura lifts its FY 2027 and FY 2028 EPS estimates for Colgate-Palmolive (India) by around 7% and 10%, respectively. It raises the stock's rating to buy from reduce and the target price to 2,500.00 rupees from 2,050.00 rupees. Shares last closed at 2,157.50 rupees. (ronnie.harui@wsj.com)

 

(END) Dow Jones Newswires

May 24, 2026 23:10 ET (03:10 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment